Clinical trial
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic…
NCT00360672 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00360672 |
|---|---|
| Title | Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome |
| Official title | Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Revlimid |
| Enrollment | 27 |
| Start date | Jan 1, 2009 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | Aug 7, 2006 |
| Last update posted | Aug 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: